With the end of the calendar looming, we’re looking back at the past year of Parkinson’s research. In a December 11 Webinar, we’ll investigate “What We Learned in 2013.”
In advance of the Webinar — for the latest in The Michael J. Fox Foundation (MJFF) Parkinson’s Podcast series — MJFF Contributing Editor Dave Iverson speaks with Kalpana Merchant, PhD, chief scientific officer of translational science at Eli Lilly and Company and a member of the MJFF Executive Scientific Advisory Board.
“There is an unprecedented number of pharmaceutical companies that are investing in Parkinson’s disease, both drug discovery and development … Alpha-synuclein remains the most intriguing, interesting target. The insight we’re getting is how the alpha-synuclein pathology is propagated from cell to cell, from region to region,” Kalpana says.
She’ll join Dave and Brian Fiske, PhD, MJFF vice president of research programs, on Wednesday, December 11, at 12 p.m. ET as part of our Hot Topics in Parkinson’s Disease Research Webinar Series. They’ll discuss key areas of interest from 2013, including biomarkers and trophic factors.
